TRCT
INKT icon

Tower Research Capital (TRC)’s MiNK Therapeutics INKT Stock Holding History

Tower Research Capital (TRC)’s Portfolio INKT Stock Details INKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.93K Buy
422
+266
+171% +$3.1K ﹤0.01% 4328
2026
Q1 		$1.64K Sell
156
-139
-47% -$1.55K ﹤0.01% 4623
2025
Q4 		$3.29K Sell
295
-631
-68% -$8.15K ﹤0.01% 4389
2025
Q3 		$13K Buy
+926
New +$14.8K ﹤0.01% 3729
2025
Q2 		– Sell
-172
Closed -$1.49K – 5412
2025
Q1 		$1.49K Sell
172
-368
-68% -$3.28K ﹤0.01% 4699
2024
Q4 		$3.76K Buy
540
+137
+34% +$932 ﹤0.01% 4597
2024
Q3 		$3.02K Sell
403
-492
-55% -$4.17K ﹤0.01% 4907
2024
Q2 		$8.49K Sell
895
-211
-19% -$2.05K ﹤0.01% 4345
2024
Q1 		$10K Buy
1,106
+12
+1% +$111 ﹤0.01% 3760
2023
Q4 		$11.7K Buy
1,094
+324
+42% +$3.38K ﹤0.01% 4108
2023
Q3 		$8.46K Sell
770
-345
-31% -$5.62K ﹤0.01% 4344
2023
Q2 		$23.4K Buy
+1,115
New +$22.3K ﹤0.01% 3244
2022
Q3 		– Sell
-110
Closed -$2K – 6265
2022
Q2 		$2K Sell
110
-117
-52% -$2.21K ﹤0.01% 5551
2022
Q1 		$5K Buy
227
+44
+24% +$1.32K ﹤0.01% 5058
2021
Q4 		$8K Buy
+183
New +$21.8K ﹤0.01% 4792

Other funds holding INKT

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DnB Asset Management
DnB Asset Management Oslo, Norway $35.7B AUM 27.58% 1-Year Est. Return
LF
Longbow Finance Lutry, Switzerland $782M AUM 48.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 29.84% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $91.6B AUM 29.2% 1-Year Est. Return

Tower Research Capital (TRC)'s INKT Position: Q2 2026 in Review

Tower Research Capital (TRC) increased its MiNK Therapeutics (INKT) stake by 171% in Q2 2026, buying an estimated $3.1K and bringing the position to 422 shares worth $4.93K. The position accounts for ﹤0.01% of the portfolio, ranked #4328.

Tower Research Capital (TRC) first reported a position in INKT in Q4 2021 and has held it in 15 quarters since. The position peaked at $23.4K in Q2 2023. 27 funds tracked by Wall St. Rank hold INKT as of Q2 2026.

  • Tower Research Capital (TRC) held 422 shares of MiNK Therapeutics worth $4.93K as of Q2 2026.
  • Tower Research Capital (TRC) bought 266 MiNK Therapeutics shares in Q2 2026, an estimated $3.1K.
  • MiNK Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #4328 holding.
  • Tower Research Capital (TRC) first reported a position in MiNK Therapeutics in Q4 2021 and has held it in 15 quarters since.
  • Tower Research Capital (TRC)'s MiNK Therapeutics position peaked at $23.4K in Q2 2023.
  • 27 funds tracked by Wall St. Rank held MiNK Therapeutics as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.